Positions

Selected Publications

Academic Article

Year Title Altmetric
2021 Antibody–drug conjugate to treat meningiomas.  Pharmaceuticals.  14. 2021
2020 A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE).  Neuro-Oncology.  22:705-717. 2020
2020 Safety and efficacy of oncolytic HSV-1 G207 inoculated into the cerebellum of mice.  Cancer Gene Therapy.  27:246-255. 2020
2019 Molecular mechanism of tumour necrosis factor alpha regulates hypocretin (orexin) expression, sleep and behaviour.  Journal of Cellular and Molecular Medicine.  23:6822-6834. 2019
2019 Diagnosing growth in low-grade gliomas with and without longitudinal volume measurements: A retrospective observational study.  PLoS Medicine.  16. 2019
2019 Characterization of iPSCs derived from low grade gliomas revealed early regional chromosomal amplifications during gliomagenesis.  Journal of Neuro-Oncology.  141:289-301. 2019
2018 Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 Expression.  Scientific Reports.  8. 2018
2018 Defining the epigenetic status of blood cells using a cyanine-based fluorescent probe for PRMT1.  Blood Advances.  2:2829-2836. 2018
2017 Elevated p53 Activities Restrict Differentiation Potential of MicroRNA-Deficient Pluripotent Stem Cells.  Stem Cell Reports.  9:1604-1617. 2017
2017 Canonical microRNAs Enable Differentiation, Protect Against DNA Damage, and Promote Cholesterol Biosynthesis in Neural Stem Cells 2017
2017 Recovery of methotrexate-induced anuric acute kidney injury after glucarpidase therapy..  SAGE Open Medical Case Reports.  5:2050313X17705050. 2017
2016 A randomized phase II trial of standard dose bevacizumab versus low dose bevacizumab plus lomustine (CCNU) in adults with recurrent glioblastoma.  Journal of Neuro-Oncology.  129:487-494. 2016
2016 Neuronal Wiskott-Aldrich syndrome protein regulates TGF-β1-mediated lung vascular permeability.  The FASEB Journal.  30:2557-2569. 2016
2016 Isorhapontigenin suppresses growth of patient-derived glioblastoma spheres through regulating miR-145/SOX2/cyclin D1 axis..  Neuro-Oncology.  18:830-839. 2016
2016 Acute disseminated encephalomyelitis presenting as a brainstem encephalitis.  Clinical Neurology and Neurosurgery.  143:76-79. 2016
2016 Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses.  Neuro-Oncology.  18:227-235. 2016
2015 Prolonged treatment with bevacizumab is associated with brain atrophy: a pilot study in patients with high-grade gliomas.  Journal of Neuro-Oncology.  122:585-593. 2015
2014 Expression of PRMT5 correlates with malignant grade in gliomas and plays a pivotal role in tumor growth in vitro.  Journal of Neuro-Oncology.  118:61-72. 2014
2014 The role of Src family kinases in growth and migration of glioma stem cells.  International Journal of Oncology.  45:302-310. 2014
2014 Transcription start site sequence and spacing between the -10 region and the start site affect reiterative transcription-mediated regulation of gene expression in Escherichia coli.  Journal of Bacteriology.  196:2912-2920. 2014
2003 The genomic sequence of ectromelia virus, the causative agent of mousepox.  Virology.  317:165-186. 2003
2002 Promotion of malignant astrocytoma cell migration by osteopontin expressed in the normal brain: Differences in integrin signaling during cell adhesion to osteopontin versus vitronectin.  Cancer Research.  62:5336-5343. 2002

Research Overview

  • Glioblastoma
    Low Grade Glioma
    Oligodendroglioma
    Astrocytome

    • Principal Investigator On

    Investigator On

  • A Phase 1 Study of M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma  awarded by National Cancer Institute/NIH/DHHS
  • A Phase I Open Label Safety Study to Evaluate the Pharmacokinetic Profile and Tolerance of Mibefradil Dose Finding in Subjects with Recurrent High-Grade Glioma Undergoing Standard. Repeated Temozolomide Treatment (TAU-2010-1)  awarded by Johns Hopkins University
  • A Phase I Trial of Anti-LAG-3 or Anti-CD137 Alone and in Combination with Anti-PD-1 in Patients with Recurrent GBM  awarded by Johns Hopkins University
  • A Phase I and Pilot Study of the Effect of rhIL-7-hyFc (NT-I7) on CD4 Counts in Patients with High Grade Gliomas and Severe Treatment-Related CD4 Lymphopenia after Concurrent Radiation and Temozolomide  awarded by Johns Hopkins University
  • A Phase II Study of Binimetinib in Combination with Encorafenib in Adults with Recurrent BRAF V600-Mutated High-Grade Astrocytoma or other Primary Brain Tumor  awarded by Johns Hopkins University
  • A Phase lb Study of Cediranib in Combination with Cilengitide in Patients with Recurrent Glioblastoma  awarded by Johns Hopkins University
  • A Pilot Study of Voraxaze(glucarpidase) in Patients with Central Nervous System Lymphoma  awarded by Memorial Sloan-Kettering Cancer Center
  • Biological Comparisons Among Three Derivative Models of Glioma Patient Cancers Under Microenvironmental Stress  awarded by National Cancer Institute/NIH/DHHS
  • Biosynthetic Metabolic Pathway Regulation of Glioma Growth  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS
  • Brain Tumor Trials Collaborative Agreement  awarded by NIH - National Institutes of Health/DHHS
  • Determining the Dose of Regadenoson Most Likely to Transiently Alter the Integrity of the Blood-Brain Barrier in Patients with High Grade Gliomas  awarded by Johns Hopkins University
  • GBM AGILE Global Adaptive Trial Master Protocol: An International, Seamless Phase II/III Response Adaptive Randomization Platform Trial Designed To Evaluate Multiple Regimens in Newly Diagnosed and Recurrent GBM  awarded by GLOBAL COALITION FOR ADAPTIVE RESEARCH
  • Individualized Screening Trial of Innovative Glioblastoma Therapy (Insight)  awarded by Dana-Farber Cancer Institute
  • Individualized Screening trial of Innovative Glioblastoma Therapy (INSIGhT)  awarded by Dana-Farber Cancer Institute
  • Modeling Low-grade Gliomas Using Human Pluripotent Stem Cells  awarded by National Institute of Neurological Disorders and Stroke/NIH/DHHS
  • NCI-CONNECT (Comprehensive Oncology Network Evaluating Rare CNS Tumors) Collaborative Agreement  awarded by National Cancer Institute/NIH/DHHS
  • NRG Oncology Member Institution Clinical Trial Fixed Price Subaward Agreement  awarded by NRG ONCOLOGY FOUNDATION
  • Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients with Recurrent High Grade Glioma  awarded by Johns Hopkins University
  • Phase 1 Dose Escalation and Drug Distribution Study of Oral Terameprocol in Patients with Recurrent High Grade Glioma (ABTC 1401)  awarded by Johns Hopkins University
  • Phase I Study of MK-1775 with Radiation and Temozolomide In Patients with Newly Diagnosed Glioblastoma and Evaluation of lntratumoral Drug Distribution in Patients with Recurrent Glioblastoma  awarded by Johns Hopkins University
  • Phase I Study to Determine the Safety and Tolerability of the Oral Microtubule Destabilizer BAL 101553 in Combination with Standard Radiation in Patients with MGMT Promoter Unmethylated Newly Diagnosed Glioblastoma  awarded by Johns Hopkins University
  • Phase I/II Study of BGB-290 with Temozolomide in Recurrent Gliomas with IDH1/2 Mutations  awarded by Johns Hopkins University
  • Phase II Study of TRC102 in Combination with Temozolomide for Recurrent Glioblastoma  awarded by Johns Hopkins University
  • Phase O/I Study of AMG 232 Concentrations in Brain Tissue in Patients with Recurrent Glioblastoma and of AMG 232 in Combination with Radiation in Patients with Newly Diagnosed Glioblastoma and Unmethylated MGMT Promoters  awarded by Johns Hopkins University
  • Pilot Study of MLN0128 in Preoperative Recurrent Glioblastoma (GBM) Patients  awarded by Johns Hopkins University
  • Private Grant  awarded by EMD SERONO
  • Private Grant  awarded by Sanofi US Services Inc
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd.
  • Private Grant  awarded by Sanofi US Services Inc
  • Private Grant  awarded by NOVARTIS PHARMACEUTICALS CORPORATION
  • Private Grant  awarded by NOVOCURE (ISRAEL) LTD
  • Private Grant  awarded by ARCHER BIOSCIENCES
  • Private Grant  awarded by ARCHER BIOSCIENCES
  • Private Grant  awarded by NOVOCURE, INC.
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
  • Private Grant  awarded by STEMLINE THERAPEUTICS INC
  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by IMMUNOCELLULAR THERAPEUTICS
  • Private Grant  awarded by NATIVIS, INC.
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
  • Private Grant  awarded by IMMUNOCELLULAR THERAPEUTICS
  • Private Grant  awarded by ORBUS THERAPEUTICS, INC.
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
  • Private Grant  awarded by BRISTOL MYERS SQUIBB PHARMACEUTICAL COMPANY
  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by ABBVIE INC
  • Private Grant  awarded by SUMITOMO DIANIPPON PHARMA ONCOLOGY INC
  • Private Grant  awarded by BIOMIMETIX JV LLC
  • Private Grant  awarded by IN8BIO INC.
  • Private Grant  awarded by AGIOS
  • Private Grant  awarded by OBLATO INC
  • Private Grant  awarded by DENOVO BIOPHARMA LLC
  • Private Grant  awarded by KARYOPHARM THERAPEUTICS, INC.
  • Single-arm, Open-label Phase II Efficacy Study of First-in-class HIF2-Alpha Inhibitor, PT2385, for Patients with Recurrent Glioblastoma  awarded by Johns Hopkins University
  • UAB NRG Oncology Master Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION
  • UAB NRG Oncology Member Institution Purchased Service Agreement  awarded by NRG ONCOLOGY FOUNDATION

    • Education And Training

  • UAB Hospital, Internship
  • UAB Hospital, Residency
  • MD Anderson Cancer Center, Postdoctoral Fellowship
  • Doctor of Philosophy in Medical Microbiology, University of Alabama at Birmingham 1998
  • Doctor of Medicine, 1987

    • Full Name

  • Xiaosi Han